Drug Profile
Insulin transdermal - Zosano Pharma
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Zosano Pharma
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 01 Sep 2016 Discontinued - Phase-I for Diabetes mellitus (Transdermal)
- 29 Sep 2015 Phase-I clinical trials in Diabetes mellitus (Transdermal)